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Introduction

27
MTHFR is a key enzyme in the one carbon unit metabolism that donates the methyl group 28 through the methionine/homocysteine cycle. SNP rs1801133, a missense mutation from cytosine 29 (C) to thymine (T) in exon 4 of MTHFR, results in a change in the amino acid sequence (alanine 30 to valine) and consequently attenuates the catalytic activity (1) . Since the first report in 1995 (2) , 31 it has been widely accepted that rs1801133 raises blood tHcy (free and protein bound 32 homocysteine). Although definitive evidence is lacking regarding the causative role of elevated 33 tHcy in various diseases, it has been generally considered as a suboptimal health condition. It is 34 common practice for physicians to recommend tHcy-lowering measures, such as vitamin Bs, for 35 rs1801133 carriers. As genotyping becomes commercially available, this practice is followed by 36 public consumers who normally receive genetic data without professional interpretation. 37 However, this practice fails to take into consideration the individual variation of this genetic 38 effect. In fact, the penetrance of this SNP is relatively small. For instance, the increase of the 39 prevalence of hyperhomocysteinemia among TT and CT carriers in US population is only 6.5% 40 and 1.8%, respectively, up from that of CC (14.4%) (3) . From this perspective, a fundamental 41 question remains unanswered: what are the measures for personalized evaluation of the risk of 42 hyperhomocysteinemia for rs1801133 carriers? 43 The low penetrance of hyprserhomocysteinemia may be due to the influence of other factors 44 (covariates) that are also known to affect plasma tHcy, including demographics (such as age, sex, 45 race), nutrition (dietary intake and supplementation of vitamin B, choline, and protein), genetics 46 (SNPs other than rs1801133), lifestyle (alcohol, smoking, and coffee), and medical treatments 47 (4) (5) (6) . These covariates may mask rs18011133's effect as independent variables (confounders). 48 More importantly, the covariates may interact with rs1801133 as effect mortifiers (or moderators) 49 Text, P5 to change its effect on tHcy, thereby defying a uniform characterization of rs1801133 effect. This 50 modifying effect has been demonstrated by several studies in which the effect of rs1801133 51 differs significantly as the status of the covariates change (3, (7) (8) (9) . 52 Given the presence of multiple effect modifiers, we would expect to see a large variability of the 53 tHcy-elevating effect of rs1801133 when it is viewed in the context of these modifiers. 54 Nonetheless, since rs1801133 is only one of the factors that impact tHcy, the actual effect of 55 rs1801133 on tHcy for any individuals who carry this variant is further complicated by the other 56 covariates. Therefore, the risk of rs1801133-derived hyperhomocysteinemia has a two-fold 57 complexity: effect modification and confounding. In this systematic review, we first made an 58 effort to delineate the variability of this genetic effect in the context of its modifiers. 59 Subsequently, we controlled for the genetic effect by genotype-stratifying the data before 60 assessing the additional variability imposed by other tHcy determinants. With this sequential 61 analysis, we attempted to address two closely related questions: 1) under what covariate-defined 62 conditions is an individual carrying rs1801133 at risk for tHcy elevation? and 2) for the 63 conditions under which a rs1801133-carrier is indeed at-risk for tHcy-elevation, what is his/her 64 risk of hyperhomocysteinemia? 65 Notably, both of the above variabilities are dependent on not only the multitude of the covariates, 66 but their combinations. As such, if a certain study determines the rs1801133 effect for a group of 67 subjects with shared status on all covariates, it provides information to only one condition of the 68 total combinations; and therefore, it would be ideal yet conceivably unattainable for a single 69 research project sufficiently powered to map out the risks under all conditions. Nonetheless, 70 global assessment can be achieved when methodologically compatible studies that investigated 71 different conditions are aggregated following the stringent procedure of systematic review. In articles and conference publications (posters and abstracts). Subsequently, we reviewed the full 96 texts to exclude the studies in which: 1) the data had been previously reported in another 97 publication; 2) the subjects were recruited exclusively from a patient population, such as the case 98 group in a case-control study; 3) the genotype/tHcy data were incomplete or missing; 4) the tHcy 99 data were provided as median instead of mean; 5) tHcy data were adjusted by variables include concentration was excluded as an independent variable for covariate analysis due to its 108 collinearity with FA intake (data not shown). To standardize data extraction for these variables, 109 we categorized each variable as detailed in Supplemental Material #4. 110 Since each of the included studies may contain one or more experimental group (named 111 "Observation") that is differentiated by the covariate status, we collected a total of 353 112 Observations from the 249 articles, and extracted data for each of the Observations that include 113 sample size, sampling date and country, genotypes, tHcy, and the status of 35 associated 114 variables. If for a certain variable the subjects in an experimental group have mixed status (such 115 as containing both males and females for sex), it is denoted as "mixed" for this Observation. If 116 information is not provided in a study for a certain covariate, it is denoted as "unknown". We examined the risk-of-bias with each Observation using Item Bank on Risk of Bias and 119 Precision of Observational Studies (10) and Cochrane Handbook for Systematic Reviews of 120 Interventions tool (11) . Since our analysis was based on the Observations instead of studies, we 121 adapted the above assessment tools to reflect the potential within-Observation bias among the 3 122 rs1801133 genotypes in selection, detection, performance, and reporting. We also considered the 123 selection bias resulted from the deviation of the subjects from the general population, such as 124 sampling from hospital patients and the healthy worker's bias. The scoring method for these 125 biases are detailed in Supplemental Material #5. Clinical trials for which the tHcy data were 126 obtained at baseline are considered as cross-sectional studies. 127 
Data synthesis and statistical analysis 128
Given the skewed distribution of tHcy in many of the reports, tHcy data were log-transformed 129 for analysis. All analyses were conducted using Comprehensive Meta-Analysis (CMA v3.0, 130 Biostat Inc., Englewood, NJ) or SAS (v9.4, SAS Institute Inc., Cary, NC). 131 Where applied, the "mixed" and "unknown" data were regarded as independent categories within 132 a variable. On rare occasions, "unknown" was combined with another category of one covariate 133 if the post hoc analysis indicated non-significant difference between these two. To ensure the 134 quality of the analysis, if the total Observation number was < 6 and subject number < 650 for one 135 category, it was excluded from analysis. We also excluded the variables that have unknown 136 status for more than 270 Observations or less than 25,000 subjects. This resulted in the retention 137 of six variables: sex, age, race, folate intake, smoking, and drinking. 138 For meta-analysis of the overall rs1801133 effect on tHcy, a pooled weighted mean difference 139 (WMD) with 95% confidence interval (CI) was calculated using random-effect model. We 140 assessed the publication bias of this effect using Begg's funnel plot and Egger's test (12) , and the 141 Text, P9 heterogeneity between the Observations using the I 2 and chi-square based Q statistic (13) . The 142 covariates' modifying and confounding effect were analyzed using regression models with ∆ Hcy 143 (CT vs. CC and TT vs. CC) and tHcy as the outcome, respectively. 144 We also used hierarchical matrix (14) to analyze how the covariates modified the rs1801133 145 effect on tHcy. In brief, we sequentially stratified the data of rs1801133 effect (∆tHcy of TT vs. 146 CC and CT vs. CC) by each of the variables, which resulted in an array of cells each containing 147 data collected under a specific multi-variable-defined condition. We then followed the random 148 effect model to aggregate the data in cells where more than one Observation was entered. Power Since the status of some variables were often not disclosed, there was a large presence of the 163 "unknown" category in these variables ( Figure 2A1 ). Accordingly, the subject numbers that 164 Text, P10 contribute to analyzing these variables' effects were limited ( Figure 2A2 ). In this respect, sex, 165 race, and age, folate intake, smoking, and drinking were the most informed variables and were 166 the variables included in subsequent statistical analyses. In addition, the category-wise 167 distribution of data within each variable was skewed by available studies. For instance, 168 compared with other race categories, the data of race is unavailable for "Oceanian" and limited 169 for Amerindian (n=1 Observation) and African (n=6 Observations). 170 Next, we examined any potential sources of bias in each Observation that may skew the tHcy Figure 2C ), suggesting the presence of publication bias. 186 2. The rs1801133 effect on tHcy is modified by multiple covariates. 187 Text, P11
Given the large heterogeneity shown in Figure 2B , we determined if this tHcy-elevating effect is 188 modified by covariates. Meta regression analysis indicate that sex, race, and FA intake are strong 189 effect modifiers (P < 0.0001) for both CT and TT genotypes ( Figure 3A) . Specifically, the tHcy- Figure 2B . 201 Since the Observations with "unknown" and "mixed" variables reduced the power of the 202 regression analysis, we next used a more stringent method (hierarchical matrix) to analyze the 203 modifiers' effect. In this method, we first removed any Observations with "unknown" or "mixed" 204 status from the dataset, and stratified the remaining data into an array of cells (n = 18 for TT and 205 8 for CT), each representing a specific combination of the variables ( Figure 3C TT and 2 out of 8 for CT; Figure 3C ). The results thus indicate that a non-discriminant risk 211 prediction based solely on rs1801133 genotype is overly simplistic. 212 3. The rs1801133 effect on tHcy is confounded by multiple covariates. 213 Next, we sought to assess the influence of rs1801133's covariates that confounded the its effect 214 on tHcy. For this purpose, we first controlled for the covariates' modifying effect by stratifying 215 the tHcy data with the three genotypes of rs1801133, and then analyzed under each genotype the 216 status of tHcy in association to the variables. As reported, tHcy was significantly affected by age, 217 sex, race, FA intake, smoking, and drinking across all three genotypes (P < 0.0001, Figure 4A , 218 Supplemental Material #11), among which smoking (even as mixed status) and race are the most 219 pronounced confounders. It is notable that the confounding effect of the covariates is in general 220 much larger in effect size than that of modifiers ( Figure 3A1 ). Nonetheless, none of the variables 221 alone dictates the incidence of hyperhomocysteinemia. In this study, we utilized published data to assess the variability of the genetic variant 236 (rs1801133)'s effect on tHcy in a covariate-dependent manner. We demonstrated systematically 237 that this genetic risk, either in its form of tHcy elevation or hyperhomocysteinemia, is not only 238 dependent on a number of covariates, but also on the combination of these covariates. For 239 instance, for a female senior East Asian with low FA intake, TT genotype does not pose a risk of 240 tHcy increase. However, the risk becomes significant if the sex status changes to a male or the 241 race to European ( Figure 3B ). Such findings highlight the caution that needs to be exercised 242 when using genetic data for predicting an individual's tHcy risk. 243 There is a large body of publications regarding rs1801133 that has accumulated since the first 244 report of this genetic risk in 1995 (2) . In this study, we collected 249 relevant articles that 245 amounts to 353 experimental groups (Observations) based on the status of 34 covariates. 246 However, as shown in Figure 2A , none of these studies provided complete information for these 247 covariates. Even for the six covariates that are most frequently informed and therefore included 248 in our regression analyses (age, sex, race, supplement, smoking, and drinking), only about a 249 quarter of the studies provided complete information. In addition, the covariates' status in some 250 study groups was indicated but indiscriminant (e.g., containing both sexes). As a result, there is a 251 large presence of missing ("unknown") and "mixed" data in our dataset, which increased the risk 252 for selection bias and decreased the power of the statistical modeling. Another power issue 253 comes from the age designation where the study group were assigned to an age category by the 254 average age, leaving the possibility of mismatch for some individuals. Nevertheless, the 255 Text, P14 modeling revealed strong modifying ( Figure 3 ) and confounding (Figure 4 ) effects, which 256 explains the high variability of reported data on rs1801133-driven tHcy elevation and 257 hyperhomocysteinemia. 258 Given the 6 covariates (age, sex, race, supplement, smoking, and drinking), we were able to 259 predict that the risk of hyperhomocysteinemia occurred in only part of the covariate-defined 260 conditions. This prediction is based on statistic modeling, which allows us not only to integrate 261 multiple studies conducted under one condition but also to interpolate from studied conditions to 262 non-studied conditions. The predicted results are yet to be validated by future studies. 263 Nonetheless, this evidence-based approach provides a reference for clinicians for whom 264 currently there is no clinical guidance on reporting this risk in a personalized way. More 265 relevantly, such information may help the general public that receive genotype data through 266 commercial service but without professional guidance. Given that rs1801133 is a relatively 267 common SNP, with an overall prevalence in our dataset of 43% for the heterozygous (CT) and 268 13% for homozygous (TT) carriers, a large number of people could potentially benefit from this 269 approach of personalized risk prediction. 270 Since we stress that only part of rs1801133 carriers are at risk for tHcy elevation and 271 hyperhomocysteinemia (Figure 3 and 4) , we paid attention to the level of stringency against false 272 negative finding (type II error) of the risk. Power analysis was conducted in the matrix analysis 273 ( Figure 3B) to ensure that the non-significant cells were not due to insufficient sample size. In 274 addition, given the publication bias towards increasing overall tHcy-elevating effect of 275 rs1801133 ( Figure 2C) , the estimated results from our analyses of this effect may be 276 overestimated but lends more support to our conclusion. Overall, our data indicate the importance of reporting the rs1801133 risk on tHcy in a covariate 278 dependent way. From this perspective, we propose that future studies obtain subjects' status of 279 relevant covariates, and that attempts are made to utilize homogeneous subject populations with 280 regards to these covariates. Such studies will not only reduce effect modification and 281 confounding, but allow risk integration in later meta analyses with increased power. 
Figure Regression analysis of the confounders of the rs1801133 effect on tHcy
